New Potential Treatment for Kidney Cancer

Karolinska

Sweden

We are looking for a better way to treat metastatic Renal Cell Cancer (RCC), which means cancer cells have spread from the kidneys to other parts of the body. For those with metastatic RCC, disease outcome is poor and available therapies may help relieve symptoms but not cure the disease. Orellanine, is a new potential medication, which specifically target cells in the kidney, including cancer cells. In this trial, we want to explore how safe and efficient orellanine is at different dose levels.

This trial will include adults with metastatic renal cell cancer who have end-stage renal disease (ESRD), the advanced stage of kidney disease where kidneys could no longer function on their own. All participants should be on hemodialysis (a process wherein a machine, instead of the kidneys, cleanses the blood) for at least 3 months.

The main goal of the trial is to find the dose of orellanine that is safe and tolerable and to learn about the effects. To take part in this trial may stop or slow your disease progression, but it’s not for sure that you will have any benefits. However, findings from this study may help other patients in the future.

Are at least 18 years old.
Have a metastatic renal cell cancer that is identified as either “clear cell renal cell cancer” (ccRCC) or “papillary renal cell cancer” (pRCC).
Have severe kidney disease where the kidneys can no longer function on their own. All participants must be on hemodialysis (a process where a machine, instead of the kidneys, cleans the blood) for at least 3 months.

Are you interested in participating in this trial?

The study is being conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital in Sweden.

The trial doctor will explain what participating in the trial will mean for you. If you agree to join, the trial doctors and other site staff will perform examinations and ask you questions about your disease, your medical history, and the medications you are taking to make sure you are eligible to take part in the trial.

If you are eligible to participate, you will receive orellanin as an infusion over 30 minutes every four weeks. You need to come to the hospital the day before the start of the treatment to receive hemodialysis. On the day of treatment, you will receive an infusion of orellanin over 30 minutes (the medicine is administered through a needle inserted into a vein in the arm). The treatment is divided into treatment cycles of 28 days each.

Participants will need to visit the study clinic regularly during each cycle. During study visits, the trial doctors will:

Give you a physical examination and check your health
Collect laboratory samples, like blood
Perform imaging tests to check your tumor status

Details about these visits and the types of tests that will be performed will be explained to you fully before you decide whether you want to join the trial.

As the study may involve travel, hotel accommodation, guest dialysis, and other additional expenses, a concierge function is ready to assist with practical arrangements. The sponsor is responsible for all these extra costs associated with the study.

The study is approved by the Swedish Ethical Review Board and the Swedish Medical Product Agency. Participation in a clinical trial is voluntary, and you can leave at any time without it affecting your treatment.

Study of Orellanine

About

Eligibility

Trial Process

Are you interested in participating in this trial?

Contact

FAQ

Frequently Asked Questions